Pluristem Therapeutics - Stock Price History | PSTI

Historical daily share price chart and data for Pluristem Therapeutics since 2021 adjusted for splits. The latest closing stock price for Pluristem Therapeutics as of September 27, 2021 is 2.77.
  • The all-time high Pluristem Therapeutics stock closing price was 3700.00 on July 15, 2003.
  • The Pluristem Therapeutics 52-week high stock price is 11.85, which is 327.8% above the current share price.
  • The Pluristem Therapeutics 52-week low stock price is 2.76, which is 0.4% below the current share price.
  • The average Pluristem Therapeutics stock price for the last 52 weeks is 5.80.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Pluristem Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 7.6745 3.8450 12.4300 2.8900 7.0700 79.44%
2019 6.1405 8.8720 11.5000 3.1900 3.9400 -50.01%
2018 12.7675 14.4000 16.1000 7.1240 7.8810 -42.89%
2017 13.5397 14.5000 20.0000 10.9000 13.8000 -3.50%
2016 14.6049 11.3000 18.5000 7.6000 14.3000 26.55%
2015 23.2807 26.9000 37.2000 9.9000 11.3000 -54.80%
2014 32.4782 37.7000 44.7000 24.1000 25.0000 -28.98%
2013 31.7695 34.0000 37.0000 26.8000 35.2000 10.34%
2012 30.2814 25.4000 47.5000 20.9000 31.9000 28.11%
2011 26.9456 15.4000 42.0000 15.4000 24.9000 74.13%
2010 12.2869 11.6000 16.4000 10.1000 14.3000 23.28%
2009 12.2406 4.5850 18.1000 4.3900 11.6000 182.93%
2008 17.4748 39.6000 50.8000 3.0000 4.1000 -88.45%
2007 125.9458 40.0000 300.0000 32.5000 35.5000 -11.25%
2006 104.8606 180.0000 220.0000 20.0000 40.0000 -77.78%
2005 400.4762 440.0000 740.0000 160.0000 180.0000 -57.14%
2004 866.9841 1300.0000 2160.0000 340.0000 420.0000 -67.69%
2003 2291.7829 3580.0000 3700.0000 1120.0000 1300.0000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.089B $0.000B
PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29